文献速递心境障碍焦虑、强迫与应激相关障碍物质与行为成瘾

美国成人DSM-5重性抑郁障碍及其标注的流行病学研究

Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States.
PubMed 文献 · JAMA Psychiatry · 2018-01-01

MDD与广泛精神障碍和物质使用障碍共病,多数终生病例为中重度,近70%接受过某种治疗,焦虑/痛苦标注占74.6%,混合特征标注占15.5%。

要点

  • 美国成人12个月和终生MDD患病率分别为10.4%和20.6%。
  • MDD与广泛精神障碍和物质使用障碍共病,严重者功能约低于全国均值1个标准差。
  • 焦虑/痛苦标注占MDD的74.6%,混合特征标注占15.5%,均与不良结局相关。

核心结论

  • 在美国成人中,DSM-5重性抑郁障碍患病率高、共病广泛且致残明显。
  • 多数病例接受过某种治疗,但仍有相当一部分未接受治疗。
  • DSM-5重性抑郁障碍标注在一般人群中的特征仍需进一步研究。

研究设计与样本

  • 数据收集于2012年4月至2013年6月,分析于2016-2017年进行。

主要发现

  • 12个月和终生MDD患病率分别为10.4%和20.6%。
  • 12个月MDD的比值比在男性为0.5(95%CI 0.46-0.55),在 African American 成人为0.6(95%CI 0.54-0.68),在 Asian/Pacific Islander 成人为0.6(95%CI 0.45-0.67),在 Hispanic 成人为0.7(95%CI 0.62-0.78),均低于白人成人。
  • MDD与特定恐怖症的aOR为2.1(95%CI 1.84-2.35),与广泛性焦虑障碍的aOR为5.7(95%CI 4.98-6.50);与酒精使用障碍的aOR为1.8(95%CI 1.63-2.01),与任何药物使用障碍的aOR为3.0(95%CI 2.57-3.55)。
  • 终生MDD病例中39.7%为中度、49.5%为重度;近70%接受过某种治疗;重度MDD者功能约低于全国均值1个标准差;12.9%的终生MDD病例所有发作均发生于亲近者死亡后且持续不足2个月。

关键数值与推荐

  • 焦虑/痛苦标注占MDD病例的74.6%,混合特征标注占15.5%。
  • 控制严重度后,焦虑/痛苦标注和混合特征标注均与早发、不良病程与功能及自杀倾向相关。

临床怎么用

  • 临床评估MDD时应关注共病精神障碍和物质使用障碍,尤其是广泛性焦虑障碍和任何药物使用障碍。
  • 对MDD患者应评估焦虑/痛苦标注和混合特征标注,因其与早发、不良病程、功能损害及自杀倾向相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: No US national data are available on the prevalence and correlates of DSM-5-defined major depressive disorder (MDD) or on MDD specifiers as defined in DSM-5. OBJECTIVE: To present current nationally representative findings on the prevalence, correlates, psychiatric comorbidity, functioning, and treatment of DSM-5 MDD and initial information on the prevalence, severity, and treatment of DSM-5 MDD severity, anxious/distressed specifier, and mixed-features specifier, as well as cases that would have been characterized as bereavement in DSM-IV. DESIGN, SETTING, AND PARTICIPANTS: In-person interviews with a representative sample of US noninstitutionalized civilian adults (≥18 years) (n = 36 309) who participated in the 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions III (NESARC-III). Data were collected from April 2012 to June 2013 and were analyzed in 2016-2017. MAIN OUTCOMES AND MEASURES: Prevalence of DSM-5 MDD and the DSM-5 specifiers. Odds ratios (ORs), adjusted ORs (aORs), and 95% CIs indicated associations with demographic characteristics and other psychiatric disorders. RESULTS: Of the 36 309 adult participants in NESARC-III, 12-month and lifetime prevalences of MDD were 10.4% and 20.6%, respectively. Odds of 12-month MDD were significantly lower in men (OR, 0.5; 95% CI, 0.46-0.55) and in African American (OR, 0.6; 95% CI, 0.54-0.68), Asian/Pacific Islander (OR, 0.6; 95% CI, 0.45-0.67), and Hispanic (OR, 0.7; 95% CI, 0.62-0.78) adults than in white adults and were higher in younger adults (age range, 18-29 years; OR, 3.0; 95% CI, 2.48-3.55) and those with low incomes ($19 999 or less; OR, 1.7; 95% CI, 1.49-2.04). Associations of MDD with psychiatric disorders ranged from an aOR of 2.1 (95% CI, 1.84-2.35) for specific phobia to an aOR of 5.7 (95% CI, 4.98-6.50) for generalized anxiety disorder. Associations of MDD with substance use disorders ranged from an aOR of 1.8 (95% CI, 1.63-2.01) for alcohol to an aOR of 3.0 (95% CI, 2.57-3.55) for any drug. Most lifetime MDD cases were moderate (39.7%) or severe (49.5%). Almost 70% with lifetime MDD had some type of treatment. Functioning among those with severe MDD was approximately 1 SD below the national mean. Among 12.9% of those with lifetime MDD, all episodes occurred just after the death of someone close and lasted less than 2 months. The anxious/distressed specifier characterized 74.6% of MDD cases, and the mixed-features specifier characterized 15.5%. Controlling for severity, both specifiers were associated with early onset, poor course and functioning, and suicidality. CONCLUSIONS AND RELEVANCE: Among US adults, DSM-5 MDD is highly prevalent, comorbid, and disabling. While most cases received some treatment, a substantial minority did not. Much remains to be learned about the DSM-5 MDD specifiers in the general population.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry. 2018. PMID: 29450462. doi:10.1001/jamapsychiatry.2017.4602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。